Advertisement: TTP Killer 50
12 April, 2012 - 22:00 By News Desk

Bicycle Therapeutics

Bicycle Greg Winter

Bicycle is developing a new class of medicines to treat cancer & other debilitating diseases. Its technology is based on work performed at the MRC Laboratory of Molecular Biology in Cambridge by the scientific founders of the company, Sir Gregory Winter (pictured) and Professor Christian Heinis. 

Bicyclic peptides are a breakthrough new therapeutic class that combine antibody-like affinity and selectivity with small molecule tissue penetration, rapid clearance and chemical synthesis. 

AstraZeneca invested in the company’s revolutionary platform in a multi-target multi-therapeutic area collaboration which has the potential to deliver revenues exceeding $1bn.


Newsletter Subscription

Stay informed of the latest news and features